A STUDY TO FIND OUT THE STEATOTIC LIVER DISEASE LINKED TO METABOLIC DYSFUNCTION AN EXPANSIVE VIEW ON A COMPLEX ISSUE

Abstract

Nonalcoholic fatty liver illness (the condition), which affects over 25% of the global population and over 60% of those at elevated risk, is becoming more and more common. It increases the risk of developing certain conditions linked to the liver and cardiovascular system as part of the metabolic syndrome. A multidisciplinary approach is necessary for the treatment of NAFLD because of the disease's complexity and the comorbidities and problems that often accompany it. However, there is a lack of knowledge Concerned among several experts on the gravity and potential consequences of fatty liver disease that is not alcoholic, as well as its comorbidities, consequences, and the necessary actions to take if NAFLD is detected. People with actively metabolising non-alcoholic steatosis (NASH) who have cirrhosis, inflexible simple steatosis, hepatocellular carcinoma, and cardiovascular disease must be identified. Unfortunately, there are conflicting recommendations for the best diagnostic and treatment methods, and this may be a challenging task. Here, we take a look back at NAFLD's origins, diagnoses, and treatment options before moving on to a discussion of potential future directions for multidisciplinary care path development.